Last reviewed · How we verify
NCT06322160: HANSOM
The Role of tHyroid cAncer Specific Patient Concerns iNventory (PCI-TC) in Enhancing Shared decisiOn Making
trial testing Interview in Thyroid Cancer in 19 participants. Completed in 3 September 2024.
3 September 2024
Quick facts
| Lead sponsor | Royal Marsden NHS Foundation Trust |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 19 |
| Start date | 3 May 2023 |
| Primary completion | 3 September 2024 |
| Estimated completion | 3 September 2024 |
| Sites | 2 locations across United Kingdom |
Drugs / interventions tested
- Interview
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
Royal Marsden NHS Foundation Trust
Who can join
18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Multiple clinical equipoises exist for the management of thyroid cancers. Shared decision-making (SDM) process where patients are supported to consider options, to achieve informed preferences with their clinicians have been recommended to improve patients' satisfaction and their overall quality of life. However, SDM can be difficult to achieve in our standard clinical encounters due to clinician's lack of confidence and time limitation to elicit patient's concerns and preferences. PCI as a decision-making support tool has shown to enhances clinician's awareness of patient's needs and allows for a more effective communication while the consultation time is unaffected. The successful development, testing and implementation of a PCI-TC could improve patient satisfaction, clinical efficiency and ensure that unmet need is appropriately addressed. This study will support the development of PCI-TC to better understand the wide-ranging needs of our patients and to improve the SDM process in the thyroid cancer management pathway.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06322160
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Interview
Trials testing the same drug.
- NCT07377006 — Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer · NA · not yet recruiting
- NCT07226102 — Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic o · NA · withdrawn
- NCT07225855 — Geriatric Assessment and Management for Older Adults Undergoing Chemotherapy and Radiation Therapy for Head and Neck Can · NA · not yet recruiting
- NCT07282444 — A New Way to Share Radiation Therapy Plans Between Doctors, CORRECT Trial · NA · not yet recruiting
- NCT07490860 — A Restorative Justice-Based Lung Cancer Screening Decision-Making Support Intervention Tailored for Black Individuals to · NA · not yet recruiting
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other Royal Marsden NHS Foundation Trust trials
Trials by the same sponsor.
- NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services · not yet recruiting
- NCT07243834 — Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise · NA · recruiting
- NCT06605833 — CARDiac Toxicity Following ImmunOtherapy Treatment for Melanoma · enrolling by invitation
- NCT07008742 — Feasibility Study of Tissue and Blood Collection in Oncogene-addicted and Neoadjuvantly Treated Non Small Cell Lung Canc · recruiting
- NCT06560905 — Preoperative Planning With PSMA-PET in Melanoma Surgery Trial · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06322160 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Royal Marsden NHS Foundation Trust
- Last refreshed: 19 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06322160.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing